Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
V114 (Vaxneuvance) in HIV-Infected Children
NCT03921424Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Nov 2019
- Primary completion
- May 2021
- Modality
- Split/Subunit Vaccines
- Countries
- 3
01
Overview
Phase 3, randomised, double-blind trial of pneumococcal 15-valent conjugate vaccine in pneumococcal infection (2 arms), sponsored by Merck & Co. Primary endpoints: Percentage of Participants With a Solicited Injection-Site Adverse Event Following Vaccination With V114 or Prevnar 13 at Day 14, Percentage of Participants With a Solicited Systemic Adverse Event Following Vaccination With V114 or Prevnar 13 at Day 14 and 2 more. Started Nov 2019; status: completed.
02
Drugs
pneumococcal 15-valent conjugate vaccine
03
Conditions
pneumococcal infection
Beyond the preview
Go deeper on NCT03921424.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03921424.